

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001157524
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Galecto, Inc.
SEC File Number 001-39655
Address of Issuer 75 State Street
Suite 100
Boston
MASSACHUSETTS
02109
Phone 45-70-70-52-10
Name of Person for Whose Account the Securities are To Be Sold The Biotech Growth Trust PLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York NY 10036	57312	41265.00	27112697	10/02/2023	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
--------------	----------	-----------	---------	----	------	-----------	---------	-----------

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	this a Gift?	Donor Acquired	Securities Acquired	Payment	Payment *
Common Stock	09/25/2020	Private Placement	Issuer	<input type="checkbox"/>		57312	09/25/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/13/2023	14700	35280.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/25/2023	8100	23652.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/31/2023	40600	121800.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/15/2023	58320	43740.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/21/2023	4809	2998.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/22/2023	2978	1846.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/23/2023	6199	3916.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/24/2023	4705	2903.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/25/2023	2712	1629.00
The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/28/2023	2158	1203.00
The Biotech Growth Trust Plc 601 Lexington Ave.	Common Stock	08/29/2023	4111	2360.00

54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/30/2023 3709	2151.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/31/2023 3102	1892.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/01/2023 7650	4667.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/05/2023 3715	2229.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/06/2023 4997	2848.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/07/2023 1302	742.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/08/2023 2887	1646.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/11/2023 4123	2309.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/12/2023 19791	12270.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/13/2023 5361	3388.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/14/2023 2110	1302.00
54th Floor New York NY 10022 The Biotech Growth Trust Plc 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/15/2023 4179	2526.00

144: Remarks and Signature

Remarks OrbiMed Capital LLC is the portfolio manager of The Biotech Growth Trust PLC.

Date of Notice 10/02/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading

instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Capital LLC, portfolio manager of The Biotech Growth Trust PLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)